Active ingredient: lisdexamfetamine dimesylate · UK and EU brand: Elvanse · Other EU markets: Venvanse
Vyvanse is the US brand name for lisdexamfetamine, one of the most-prescribed long-acting ADHD stimulants in North America. A once-daily amphetamine prodrug your body activates gradually, producing a smooth onset and a long tail.
The lisdexamfetamine prodrug, in plain English.
Vyvanse is a prodrug your body activates gradually. Unlike immediate-release amphetamines that enter the bloodstream directly, lisdexamfetamine must be converted by enzymes (primarily in red blood cells) into dextroamphetamine before it becomes active. This conversion is steady, which gives Vyvanse its characteristically smooth onset and extended duration.
After you take your dose, levels begin to rise within an hour or two. Peak concentration is reached around three to four hours after dosing. From that peak, levels decline steadily through the rest of the day. Coverage typically runs ten to fourteen hours.
Why a prodrug? The prodrug design gives two practical benefits beyond pharmacology: the medication cannot be inhaled or injected to produce a faster effect (the body still has to do the conversion), and the conversion rate is relatively consistent across individuals, which makes the dose-response more predictable.
Vyvanse's close relations.
Vyvanse is one of three amphetamine-based ADHD medications prescribed in the US.
Finding your dose.
US Vyvanse titration typically starts at 30mg and increases in defined steps to 50mg, then 70mg, based on response. Each level is usually maintained for two to four weeks before review. Maximum US adult dose is 70mg per day.
Available US doses: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg.
Most people take Vyvanse first thing in the morning. The combination of a one- to two-hour onset and a ten- to fourteen-hour duration means dose timing decides where the medication sits in your day. Taking it earlier moves the entire profile earlier, which has direct implications for sleep readiness.
Vyvanse can be taken with or without food. Taking it with breakfast may slightly delay the onset (around thirty minutes) but does not reduce the overall effect. Capsule contents can be dissolved in water, orange juice or yogurt for adults who have difficulty swallowing capsules.
ADHDose models your Vyvanse profile using the published pharmacokinetic data, calibrated to your dose, your timing and your individual metabolism. The app translates that into real-time guidance through your day, calculates a personalised wind-down window, and exports a Clinician Summary PDF for prescriber appointments.
The Vyvanse curve, your dose, your day.
Vyvanse rises gradually after dosing, peaks around four hours in, then declines through the afternoon and evening. The exact shape depends on you. ADHDose calculates your specific curve in real time.
ADHDose reads your prescription, calibrates to your individual response and shows you exactly where you are in your medication day. The Clinician Summary export pulls 28 days of patterns into prescriber-ready PDF for review appointments.
The app reads your prescription, builds your personal curve from how your own days actually go, and tells you where you are in your medication day, minute by minute.
Every figure here is taken straight from the prescribing information, with the source on each row.
| Parameter | What the label states | Source |
|---|---|---|
| Active molecule | Lisdexamfetamine is a prodrug, converted to dextroamphetamine by red blood cells | FDA label |
| Tmax (capsule, fasted) | Prodrug Tmax approximately 1 hour; active moiety approximately 3.5 hours (paediatric) | FDA label |
| Half-life (dextroamphetamine) | Approximately 10 to 11.3 hours in adults (8.6 to 9.5 hours in children) | FDA label |
| Typical adult dose (US) | 30 to 70 mg/day; start 30 mg, titrate by 10 or 20 mg weekly | FDA label |
| Food effect (capsule) | No effect on AUC/Cmax; delays Tmax by approximately 1 hour (3.8 to 4.7 hours) | FDA label |
Half-life and Tmax figures are for the active moiety dextroamphetamine, not for lisdexamfetamine itself, which is an inactive prodrug with its own much shorter (under 1 hour) plasma half-life.
Not stated in the label: Duration of effect: the FDA label does not state a formal clinical duration-of-effect figure in Section 12.
Common side effects.
Most people tolerate Lisdexamfetamine well, especially after the first few weeks. Here are the patterns worth noticing, and the ones that warrant a call to your prescriber.
Most ease in the first two to four weeks. Logging them daily helps you and your prescriber decide whether they are settling or sticking.
Not emergencies, but worth bringing up. ADHDose tags recurring patterns automatically in your daily logs.
Rare, but worth knowing. If you see any of these, contact your prescriber rather than stopping on your own.
Titration, week by week.
The first weeks of Lisdexamfetamine have a recognisable shape. Knowing what is normal at each stage stops you reading too much into a single bad day.
Most people feel something within the first hour of the first dose. The first few days often involve small wobbles: appetite changes, sleep shifts, occasional headaches. None of this is unusual. Daily logging helps separate first-dose nerves from real side effect patterns.
Side effects from days one to three usually start to ease. The dose-response becomes more predictable. Track focus, sleep and energy daily. This is the data your prescriber wants at your first review.
Most UK and US protocols schedule the first review around week two or four. Your prescriber will ask about effect, side effects, sleep and appetite. Bringing tracked data, rather than relying on memory, turns the review from vague impressions into something concrete.
If the first dose is not quite right, your prescriber will adjust upward in defined steps. Each step is usually held for two to four weeks before the next adjustment. The same daily logging continues.
Once the dose is settled, reviews shift to every six to twelve months. Daily logging becomes lighter; focus and sleep are usually enough. The Clinician Summary export gives prescribers a 28-day window of evidence at each review.
ADHDose makes the milestone view concrete. Daily logs of focus, sleep, energy and side effects across the titration window show the trajectory clearly, to you, and to your prescriber when review day arrives.